Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

NextEdge Admin

23 Dec 2024

2 min 50 sec

SCG Cell Therapy Pte Ltd, a biotechnology company specializing in immunotherapies for infectious diseases and related cancers, has signed a Memorandum of Understanding (MoU) with A*STAR's Bioprocessing Technology Institute (BTI) and the Nucleic Acid Therapeutics Initiative (NATi). This partnership aims to accelerate the development and commercialization of RNA-based therapeutics and mRNA vaccines.

The MoU leverages A*STAR BTI and NATi's expertise in bioprocessing, biomarker discovery, and target validation, alongside SCG's local GMP manufacturing and global clinical development capabilities. Collaborative efforts will focus on RNA manufacturing process development, analytics, automation, and digitalization. A joint laboratory will be established at SCG's GMP manufacturing facility in Singapore, complemented by a talent development program to train scientists and engineers in Good Manufacturing Practices (GMP).

This partnership builds on a history of collaboration between SCG and A*STAR, including the establishment of joint laboratories for cellular immunotherapies in April 2024, supported by nearly S$30 million under Singapore's Research, Innovation, and Enterprise 2025 Plan (RIE2025). The initiative focuses on scalable GMP-grade induced pluripotent stem cells (iPSC) and therapeutic product development.

RNA-based therapeutics, which leverage nucleic acids to modify genetic material within cells, hold promise for treating cancers and viral infections. These therapies utilize the body’s mechanisms to produce therapeutic proteins or alter gene expression, addressing diseases that are difficult to treat with conventional methods.

“RNA therapies have the potential to revolutionize disease treatment,” said Christy Ma, Chief Strategy Officer of SCG. “This collaboration enhances our ability to develop high-quality, affordable treatments for patients.”

Dr. Koh Boon Tong, Executive Director of A*STAR BTI and NATi, emphasized the importance of public-private partnerships in advancing innovation and building Singapore’s capabilities in mRNA biomanufacturing, establishing RNA therapeutics as a cornerstone of the nation’s pharmaceutical industry.